RxDoctor Payments Data

Paula McCarter-Carlisle

Family · Jasper, INNPI 1942895958

Payments from drug & device makers

$6,323in general payments, 2019–2025

Across 336 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$801
  • Seagen Inc.$520
  • AbbVie$355
  • Daiichi Sankyo Inc.$343
  • Incyte Corporation$322
  • Bristol Myers Squibb$308
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$5,76591%
  • Education$5589%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis50$801
Seagen Inc.21$520
AbbVie14$355
Daiichi Sankyo Inc.20$343
Incyte Corporation12$322
Bristol Myers Squibb13$308
Pfizer19$297
AstraZeneca(2 entities)17$286
Sanofi13$271
Merck14$260
Eisai Inc.13$251
Amgen14$219
Johnson & Johnson7$181
E.r. Squibb & Sons, L.L.C.9$131
Genentech USA, Inc.6$105
Lilly USA, LLC6$96
Adaptive Biotechnologies Corporation5$95
Takeda Pharmaceuticals U.S.A., Inc.4$93
Ipsen Biopharmaceuticals, Inc5$82
Pharmacyclics LLC, An Abbvie Company5$73
Tersera Therapeutics LLC4$73
Sun Pharmaceutical Industries Inc.3$70
Blueprint Medicines Corporation3$64
Bayer4$62
Astellas Pharma US Inc4$57
Karyopharm Therapeutics Inc.3$57
Coherus Oncology, Inc.2$48
Boehringer Ingelheim3$47
Syndax Pharmaceuticals, Inc.2$46
Cumberland Pharmaceuticals, Inc.2$42
Pharmaessentia USA Corporation2$40
Puma Biotechnology, Inc.2$37
Gilead(2 entities)2$35
Exelixis Inc.2$35
ADC Therapeutics America, Inc.1$34
Taiho Oncology, Inc.2$32
Acrotech Biopharma Inc.2$32
AMAG Pharmaceuticals, Inc.2$32
Beone Medicines USA, Inc.2$31
Kyowa Kirin, Inc.2$29
Organon2$27
Geron Corporation1$27
Regeneron Healthcare Solutions, Inc.1$24
TG Therapeutics, Inc.1$23
Genmab U.S., Inc.1$22
Aadi Bioscience, Inc.1$19
Stemline Therapeutics Inc.1$18
Tempus AI, Inc1$18
Recordati_rare_diseases_inc.1$15
Array Biopharma Inc1$15
Foundation Medicine, Inc.1$14
Pharmacosmos Therapeutics Inc.1$14
Jazz Pharmaceuticals Inc.1$14
Acceleron Pharma, Inc.1$14
Rigel Pharmaceuticals, Inc.1$14
Dova Pharmaceuticals1$14
GSK1$14
Sobi, Inc1$13
Deciphera Pharmaceuticals Inc.1$12

How this compares

$6,323 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$67,301
Medicare patients
385
Services billed
1,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide14$202,308
EliquisApixaban33$22,982
Hydroxyurea31$778
Anastrozole53$607
Pantoprazole Sodium43$582
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$555
Letrozole32$527
Ondansetron OdtOndansetron29$464
ValacyclovirValacyclovir Hcl13$362
Potassium Chloride25$283
Morphine Sulfate ErMorphine Sulfate14$281
Hydrocortisone29$252
Acyclovir17$239
Tamoxifen Citrate14$235
Prochlorperazine Maleate16$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$22,98233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Jasper

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →